Advaxis, Inc. Stock Nasdaq
Equities
US0076242082
Biotechnology & Medical Research
Sales 2022 | 692K 945K | Sales 2023 | 13K 17.75K | Capitalization | 7.94M 10.84M |
---|---|---|---|---|---|
Net income 2022 | -38M -51.89M | Net income 2023 | -48M -65.54M | EV / Sales 2022 * | - |
Net cash position 2022 | 657K 897K | Net Debt 2023 | 3.43M 4.69M | EV / Sales 2023 | 875 x |
P/E ratio 2022 * |
-
| P/E ratio 2023 |
-0.08
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 0% |
Managers | Title | Age | Since |
---|---|---|---|
Ken Berlin
CEO | Chief Executive Officer | 59 | 18-04-22 |
- | - | ||
- | - |
Members of the board | Title | Age | Since |
---|---|---|---|
David Sidransky
CHM | Chairman | 64 | 13-07-15 |
Roni Appel
CEO | Chief Executive Officer | 57 | 04-10-31 |
Murray Goldberg
BRD | Director/Board Member | 79 | 23-01-18 |
1st Jan change | Capi. | |
---|---|---|
+44.48% | 55.07B | |
+43.74% | 40.22B | |
-0.86% | 41.79B | |
-7.59% | 28.17B | |
+12.30% | 26.28B | |
-21.83% | 18.93B | |
+7.15% | 13.03B | |
+29.40% | 12.26B | |
+25.15% | 12.21B |